Imperial College London researchers have found that giving low‑dose statins to people who are currently healthy can cut the chance of a heart attack or stroke by roughly 25% over ten years. The study, which pooled data from more than 100,000 participants across seventeen trials, compared early‑start users with those who waited until their risk rose. Findings were unveiled at the European Atherosclerosis Society Congress in Athens,prompting calls to rethink NHS prescribing rules.

25% Reduction Linked to Modest LDL Drop in Low‑Risk Cohort

According to the analysis,a modest reduction in low‑density lipoprotein (LDL) cholesterol among participants initially classified as low‑risk produced a 25% decline in major cardiovascular events over the subsequent decade. Dr Irene Karungi of Imperial’s School of Public Health emphasized that the benefit of early LDL lowering far exceeds the advantage of treating patients only after their risk scores climb.

Current NHS Guidelines May Be Too Conservative, Say Researchers

The authors argue that NHS policy, which typically reserves statins for patients with elevated cholesterol or a prior cardiac episode, could be missing a preventive window . By starting a modest dose earlier, doctors could achieve comparable protection while exposing patients to fewer side‑effects, because the required dosage would be smaller than that used in later‑stage treatment.

Projected Surge to Ten Million Cardiovascular Cases by 2040 Fuels Urgency

Health officials estimate that more than seven million Britons now take cholesterol medication, yet projections warn that cardiovascular disease diagnsoes could climb to ten million by 2040. Professor Kausik Ray, co‑author of the study, likened early statin use to a penssion scheme: the sooner contributions begin, the larger the eventual benefit for the health system.

Key Unknowns: Optimal Dose and Long‑Term Safety Remain Unclear

While the data are compelling, the study acknowledges that further research is needed to pinpoint the ideal low‑dose regimen and to assess long‑term safety. The analysis does not address potential variations in adherence among healthy individuals or the impact of lifestyle factors that could modify statin effectiveness.

What Critics May Question: Who Will Pay for Wider Prescribing?

Some health‑economics experts may wonder how the NHS will fund a broader rollout of statins to millions of low‑risk patients. The report does not provide a cost‑benefit analysis, leaving policymakers to weigh drug expenses against the projected reduction in heart‑related hospitalisations.